109 related articles for article (PubMed ID: 38741506)
21. [Paraneoplastic Cerebellar Degeneration with Lambert-Eaton Myasthenic Syndrome: A Report of an Effectively Treated Case and Systematic Review of Japanese Cases].
Kitanosono H; Motomura M; Tomita H; Iwanaga H; Iwanaga N; Irioka T; Shiraishi H; Tsujino A
Brain Nerve; 2019 Feb; 71(2):167-174. PubMed ID: 30718446
[TBL] [Abstract][Full Text] [Related]
22. Lambert-Eaton myasthenic syndrome as an autoimmune calcium-channelopathy.
Takamori M; Maruta T; Komai K
Neurosci Res; 2000 Mar; 36(3):183-91. PubMed ID: 10683522
[TBL] [Abstract][Full Text] [Related]
23. Apheresis treatment in Lambert-Eaton myasthenic syndrome.
Motomura M; Hamasaki S; Nakane S; Fukuda T; Nakao YK
Ther Apher; 2000 Aug; 4(4):287-90. PubMed ID: 10975475
[TBL] [Abstract][Full Text] [Related]
24. Lambert-Eaton syndrome antibodies target multiple subunits of voltage-gated Ca2+ channels.
Hajela RK; Huntoon KM; Atchison WD
Muscle Nerve; 2015 Feb; 51(2):176-84. PubMed ID: 24862203
[TBL] [Abstract][Full Text] [Related]
25. GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome.
Shimizu F; Takeshita Y; Sano Y; Hamamoto Y; Shiraishi H; Sato T; Yoshimura S; Maeda T; Fujikawa S; Nishihara H; Kitanosono H; Tsujino A; Motomura M; Kanda T
Brain; 2019 Aug; 142(8):2253-2264. PubMed ID: 31236596
[TBL] [Abstract][Full Text] [Related]
26. Lambert-Eaton myasthenic syndrome.
Newsom-Davis J
Rev Neurol (Paris); 2004 Feb; 160(2):177-80. PubMed ID: 15034474
[TBL] [Abstract][Full Text] [Related]
27. Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer.
Payne M; Bradbury P; Lang B; Vincent A; Han C; Newsom-Davis J; Talbot D
J Thorac Oncol; 2010 Jan; 5(1):34-8. PubMed ID: 19934775
[TBL] [Abstract][Full Text] [Related]
28. Voltage gated calcium channel antibody-related neurological diseases.
Bekircan-Kurt CE; Derle Çiftçi E; Kurne AT; Anlar B
World J Clin Cases; 2015 Mar; 3(3):293-300. PubMed ID: 25789302
[TBL] [Abstract][Full Text] [Related]
29. Presynaptic Disorders: Lambert-Eaton Myasthenic Syndrome and Botulism.
Gable KL; Massey JM
Semin Neurol; 2015 Aug; 35(4):340-6. PubMed ID: 26502758
[TBL] [Abstract][Full Text] [Related]
30. Lambert-Eaton myasthenic syndrome.
Mareska M; Gutmann L
Semin Neurol; 2004 Jun; 24(2):149-53. PubMed ID: 15257511
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of intravenous immunoglobulin for treatment of Lambert-Eaton myasthenic syndrome without anti-presynaptic P/Q-type voltage-gated calcium channel antibodies: a case report.
Okada A; Koike H; Nakamura T; Motomura M; Sobue G
Neuromuscul Disord; 2015 Jan; 25(1):70-2. PubMed ID: 25444432
[TBL] [Abstract][Full Text] [Related]
32. Long-term observation of incremental response and antibodies to voltage-gated calcium channels in patients with Lambert-Eaton myasthenic syndrome: two case reports.
Schneider I; Kornhuber ME; Hanisch F
J Med Case Rep; 2015 Mar; 9():59. PubMed ID: 25885033
[TBL] [Abstract][Full Text] [Related]
33. Low specificity of voltage-gated calcium channel antibodies in Lambert-Eaton myasthenic syndrome: a call for caution.
Di Lorenzo R; Mente K; Li J; Shayya L; Rae-Grant A; Li Y; Jammoul A
J Neurol; 2018 Sep; 265(9):2114-2119. PubMed ID: 29987589
[TBL] [Abstract][Full Text] [Related]
34. Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction.
Pellkofer HL; Voltz R; Kuempfel T
Muscle Nerve; 2009 Aug; 40(2):305-8. PubMed ID: 19609921
[TBL] [Abstract][Full Text] [Related]
35. A case report of the efficient reduction of calcium channel antibodies by tryptophan ligand immunoadsorption in a patient with Lambert-Eaton syndrome.
Sauter M; Bender A; Heller F; Sitter T
Ther Apher Dial; 2010 Jun; 14(3):364-7. PubMed ID: 20609193
[TBL] [Abstract][Full Text] [Related]
36. Increased frequency of HLA class II alleles DRB1*0301 and DQB1*0201 in Lambert-Eaton myasthenic syndrome without associated cancer.
Parsons KT; Kwok WW; Gaur LK; Nepom GT
Hum Immunol; 2000 Aug; 61(8):828-33. PubMed ID: 10980394
[TBL] [Abstract][Full Text] [Related]
37. Antibodies to active zone protein ERC1 in Lambert-Eaton myasthenic syndrome.
Huijbers MG; Lipka AF; Potman M; Hensbergen PJ; Titulaer MJ; Niks EH; van der Maarel SM; Klooster R; Verschuuren JJ
Hum Immunol; 2013 Jul; 74(7):849-51. PubMed ID: 23583364
[TBL] [Abstract][Full Text] [Related]
38. Lambert-eaton myasthenic syndrome differential reactivity of tumor versus non-tumor patients to subunits of the voltage-gated calcium channel.
Pellkofer HL; Armbruster L; Krumbholz M; Titulaer MJ; Verschuuren JJ; Schumm F; Voltz R
J Neuroimmunol; 2008 Nov; 204(1-2):136-9. PubMed ID: 18809213
[TBL] [Abstract][Full Text] [Related]
39. An autoimmune channelopathy associated with cancer: Lambert-Eaton myasthenic syndrome.
Takamori M
Intern Med; 1999 Feb; 38(2):86-96. PubMed ID: 10225662
[TBL] [Abstract][Full Text] [Related]
40. Antibodies to calcium channel and synaptotagmin in Lambert-Eaton myasthenic syndrome.
Takamori M; Komai K; Iwasa K
Am J Med Sci; 2000 Apr; 319(4):204-8. PubMed ID: 10768604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
